For most of its existence, cystic fibrosis was a death sentence delivered in childhood. Then came a drug that could genuinely change that – one so effective it was called a turning point in the history of the disease. The catch was the price tag, which happened to be more than most people earn in a decade.
That drug is Trikafta, and it costs $370,000 a year in the United States. For the roughly 188,000 people living with cystic fibrosis worldwide, that number has functioned less like a price and more like a locked door. Most patients have watched from the other side of it. Now, a pharmaceutical company in Bangladesh has made a copy of the key – and is offering it for $12,750.
The math is almost hard to absorb. At that price, 58 children could be treated for the cost of a single year of the branded product. The company is Beximco Pharmaceuticals, a Bangladeshi generic drug manufacturer that reverse-engineered one of the most expensive drugs on earth, priced it 96% lower, and handed it directly to patients from six countries at a ceremony in Dhaka.
What Cystic Fibrosis Actually Does – and Why This Drug Matters
Cystic fibrosis is a life-threatening genetic condition, and for years, a group of families frustrated by Trikafta’s price worked with a generic manufacturer to build a buyers’ club and distribute the medication in countries where the cost was out of reach. The science behind what they were fighting for is worth understanding.
Trikafta is a combination of elexacaftor, tezacaftor, and ivacaftor. Cystic fibrosis is caused by a defect in a gene called CFTR, which normally instructs cells to move salt and water across their membranes. When that gene is faulty, thick, sticky mucus builds up in the lungs, digestive system, and other organs – slowly destroying them. Trikafta has transformed treatment outcomes and significantly improved survival rates for CF patients.
The three drugs in Trikafta work through two distinct mechanisms. Elexacaftor and tezacaftor act as correctors – they bind to the faulty CFTR protein and help it fold correctly so it can reach the surface of the cell. Ivacaftor then functions as a potentiator, binding to the CFTR protein and holding the channel open so that salt can pass through it. The most common genetic culprit underlying this dysfunction is the F508del mutation, the most widespread CF-causing genetic defect – and Trikafta was designed to address it.
The Scale of Who Gets Left Out – and the Cystic Fibrosis Drug Cost Gap
An estimated 188,336 people have cystic fibrosis around the world, but only 27% of them currently receive treatment. Triko is offered at $6,375 per child and $12,750 per adult per year – figures confirmed by both Beximco and the patient coalition that spearheaded the project. That treatment gap is not random. It maps almost exactly onto wealth.
Researchers have estimated that around 82% of undiagnosed CF patients live in low- and middle-income countries. Meanwhile, just one such country reported patient reimbursement for Trikafta, compared with 35 high-income countries. In some nations, lack of diagnosis and treatment means many people with CF still do not reach the age of 20.
The drug generating this disparity is also one of the best-selling pharmaceuticals on earth. Vertex Pharmaceuticals reported full-year product revenue of $11.02 billion in 2024, driven primarily by Trikafta. The company has maintained robust patent protections across most major markets, meaning no generic competition has been able to emerge – until now, and only in a very specific legal context.
The Legal Loophole That Made Triko Possible
Bangladesh occupies an unusual position in global trade law. Beximco Pharma is headquartered in Bangladesh, a country classified as a Least Developed Country by the United Nations. Under the World Trade Organization’s Agreement on Trade-Related Aspects of Intellectual Property Rights, Least Developed Country member states are exempt from enforcing pharmaceutical patents – and Beximco said this exemption provides the legal basis for the company to manufacture and export generic versions of patented medicines. According to the WTO, the transition period for least-developed country members extends until January 1, 2033, or until a country graduates out of that status. Bangladesh has used that window to do something no other country has managed at this scale with this particular drug.
The initiative that brought Triko into being didn’t start in a boardroom. The announcement was made on October 23 at the North American Cystic Fibrosis Conference in Seattle, Washington, by a coalition of mothers of children living with CF. Patients were the ones who first led Beximco to develop Triko three years ago. The effort was coordinated by the Right to Breathe campaign, a patient-led movement challenging Vertex over its drug pricing. The campaign was built from a grassroots network of CF families who teamed up with advocacy organizations including Just Treatment, Third World Network, and Health Justice Initiative to push for generic access across borders.
The CF Buyers’ Club Model
The generic supply will be managed on a named-patient basis through the CF Buyers’ Club, with plans to expand access gradually. A named-patient basis means each individual receiving the drug must be registered – it’s not simply available on open sale, but rather distributed through a structured, clinician-involved process that ensures patients are appropriately identified and monitored.
The CF Buyers’ Club emerged directly from patient advocacy pressure. The community-led model coordinates access for patients and clinicians globally, supported by advocacy groups including Just Treatment, Third World Network, and Health Justice Initiative.
Beximco Pharmaceuticals launched Triko as an affordable generic version of one of the world’s most effective treatments for cystic fibrosis, formally handing it over to CF patients and representatives from six countries – including the US, UK, and South Africa – at its manufacturing facility in Tongi on June 15, 2026. The medicine, a combination of elexacaftor, tezacaftor, and ivacaftor, also known as ETI, was handed over at a ceremony held at the company’s manufacturing facility in Dhaka.
Beximco also launched a companion product alongside Triko. The company introduced Bexdeco, a generic version of ivacaftor – one of the three active components – priced at $5 per tablet. That single-component option matters for patients who may be eligible for ivacaftor alone based on their specific genetic mutation.
What Vertex Has Said – and What It Hasn’t
Vertex has not publicly welcomed the development. The company did not directly respond to requests for comment on the purchasing group’s announcement when the buyers’ club was first revealed. Vertex has continued expanding its CF pipeline, recently gaining FDA approval for Alyftrek, a once-daily successor to Trikafta for CF patients aged six and older, and is pursuing regulatory submissions for even younger age groups. Trikafta remains protected by a significant patent estate and regulatory exclusivity in major markets such as the US and EU, helping preserve its role as a revenue driver.
The pricing debate around Trikafta predates this year’s developments by some distance. A 2023 Fierce Pharma article noted that a coalition of CF patients and families petitioned governments in South Africa, Brazil, India, and Ukraine to either revoke or suspend Trikafta patents – a sign of how long the tension over access had been building before Bangladesh’s solution arrived.
Read More: Diabetes Medicine Linked to Lower Dementia Risk, Scientists Find
What Families Can Do Now
If you or someone close to you is living with cystic fibrosis outside of a high-income country with reimbursed access to Trikafta, Triko’s launch represents a concrete new option. The CF Buyers’ Club at cfbuyersclub.org is the access point – patients, families, and clinicians can register interest there and connect with the named-patient supply process.
Rare disease drug pricing has long operated under a logic largely unchallenged in high-income markets – that a company’s investment in R&D justifies whatever price the patent system permits. What happened in Dhaka on June 15, 2026 was not a government decision or an act of policy. It was patient advocacy, civil society pressure, and generic manufacturing combining to challenge a pharmaceutical monopoly in a rare disease – and producing a result: $12,750 a year for a treatment that otherwise costs $370,000. For families who have spent years watching a child deteriorate while that treatment sat legally out of reach, that price difference is the entire story.
Disclaimer: This information is not intended to be a substitute for professional financial advice, investment advice, tax advice, or legal advice, and is provided for informational purposes only. Always seek the guidance of a qualified financial advisor, accountant, or other licensed professional regarding your personal financial situation or investment decisions. Do not make financial, investment, or tax decisions based solely on information presented here. Past performance is not indicative of future results, and all investments carry risk, including the potential loss of principal.
AI Disclaimer: This article was created with the assistance of AI tools and reviewed by a human editor.